Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

Date: 
2 Nov 2017
Source: 
Clinical Cancer Research
Audience: 
Professionals
Type of resource: 
Research

Resistance to platinum-based chemotherapy or PARP inhibition in germline BRCA1 or BRCA2 mutation carriers may occur through somatic reversion mutations or intragenic deletions that restore BRCA1 or BRCA2 function. 

 

Click here to read the Research article in full